약물 남용 치료 시장 : 치료 방법, 약물 유형별, 약제 클래스별, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Substance Abuse Treatment Market is projected to grow by USD 21.32 billion at a CAGR of 7.26% by 2032.

Substance Abuse Treatment Market Introduction

Substance abuse treatment is moving from episodic detoxification toward integrated, evidence-based care for substance use disorders, including opioid use disorder, alcohol use disorder, stimulant use disorder, and polysubstance use. The market is shaped by rising overdose risk, broader mental health awareness, and demand for medication-assisted treatment, behavioral therapy, harm reduction, and long-term recovery support.

Verified public health data underline the urgency. UNODC reported that 292 million people used drugs in 2022, 64 million lived with drug use disorders, and only about one in eleven people with drug use disorders received treatment. WHO has also linked alcohol consumption to approximately 2.6 million deaths annually and psychoactive drug use to hundreds of thousands of deaths, reinforcing substance abuse treatment as a core healthcare priority.

Transformative Shifts in the Treatment Landscape

The treatment landscape is being reshaped by wider acceptance of medication-assisted treatment, expansion of telehealth, community-based recovery models, and policy support for naloxone access. Care providers are increasingly combining detoxification, residential treatment, outpatient programs, peer support, and co-occurring mental health care to reduce relapse risk and improve continuity.

Major shifts include a move from punitive drug policy toward public health responses, value-based reimbursement, and integrated behavioral health. In the United States, FDA approval of over-the-counter naloxone in 2023 and expanded buprenorphine prescribing flexibility strengthened access, while similar harm reduction and treatment integration efforts are advancing across Europe, Canada, Australia, and parts of Asia-Pacific.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly relevant to substance abuse treatment through risk stratification, relapse prediction, patient engagement, clinical documentation, and population health management. AI-enabled tools can analyze electronic health records, claims data, screening results, and wearable signals to identify patients who may need early intervention or stepped-up support.

The cumulative impact depends on governance. AI can improve referral matching, automate intake workflows, support virtual counseling, and personalize recovery plans, but substance use disorder data require rigorous privacy, bias mitigation, explainability, and clinical oversight under frameworks such as HIPAA, GDPR, and emerging AI safety regulations.

Key Regional Insights: Global Demand and Access

North America remains a highly mature substance abuse treatment region, driven by high opioid use disorder burden, Medicaid and commercial reimbursement, established medication-assisted treatment infrastructure, and strong private provider networks. Europe is advancing through public health systems, the European Union drugs strategy, opioid substitution therapy, and harm reduction models, while the United Kingdom, Germany, France, Italy, and Spain continue to balance treatment access with workforce constraints and regional differences in service delivery.

Asia-Pacific is expanding from a lower treatment penetration base as China, India, Japan, South Korea, and Australia increase investment in mental health, digital health, and community intervention. Latin America, led by Brazil and Mexico, faces rising demand for affordable addiction treatment and public-private service models amid alcohol, stimulant, and opioid-related challenges. The Middle East, especially GCC markets, is building specialized behavioral health capacity and confidentiality-centered care, while Africa has a significant unmet need due to limited trained workforce, stigma, underfunded treatment systems, and constrained access to evidence-based addiction medicine.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gradually strengthening substance abuse treatment through public health campaigns, rehabilitation capacity, and cross-border drug control cooperation, though treatment access remains uneven across income levels and urban-rural settings. The GCC is investing in behavioral health infrastructure, addiction rehabilitation, and confidentiality-focused care models as mental health policy modernization improves demand visibility and encourages earlier engagement with treatment services.

The European Union benefits from coordinated drug monitoring, harm reduction standards, opioid agonist treatment availability, and publicly funded treatment systems, while BRICS countries represent high-volume demand with diverse regulatory, reimbursement, and public health environments across Brazil, Russia, India, China, and South Africa. G7 countries lead in evidence-based addiction medicine, naloxone access, digital health adoption, and integrated behavioral healthcare, and NATO members increasingly recognize substance use treatment as part of military readiness, veteran health, trauma-informed care, and resilience planning.

Key Country Insights: Priority Markets for Substance Abuse Treatment

The United States faces a severe overdose burden and continues to expand medication-assisted treatment, naloxone access, behavioral health integration, and payer-supported recovery programs, while Canada emphasizes harm reduction, supervised consumption services, safer supply discussions, and opioid agonist therapy. Mexico and Brazil face growing demand for scalable public and private treatment models, with Brazil showing strong need for alcohol and drug rehabilitation capacity and Mexico addressing cross-border drug supply pressures and community-based treatment gaps.

In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on established public health systems but need faster access, workforce expansion, and integrated mental health support; Russia maintains a distinct regulatory approach to opioid substitution therapy, affecting treatment modality availability. China and India offer significant public health relevance through mental health reform, large population needs, and digital care scale, while Japan, Australia, and South Korea are characterized by higher healthcare quality, growing telehealth use, and rising attention to alcohol, stimulant, opioid, and behavioral health comorbidities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based treatment models that combine medication-assisted treatment, cognitive behavioral therapy, contingency management, peer recovery support, overdose prevention, and coordinated care for co-occurring mental health conditions. Programs should track retention, relapse, overdose reversal, patient-reported outcomes, treatment engagement, and social determinants such as housing, employment, family support, and criminal justice involvement.

Providers and investors should build hybrid care models, partner with payers and public agencies, expand culturally competent care, and strengthen workforce training for addiction medicine, psychiatry, counseling, and peer support. Digital tools should be deployed only with clear clinical validation, privacy safeguards, and measurable improvement in access, adherence, retention, and long-term recovery outcomes.

Research Methodology and Evidence Base

This executive summary is based on triangulation of public health databases, regulatory updates, peer-reviewed addiction medicine literature, and institutional sources including WHO, UNODC, CDC, SAMHSA, FDA, and European drug monitoring authorities. Market interpretation considers treatment access, policy direction, reimbursement, clinical evidence, disease burden, workforce capacity, and regional care infrastructure.

The methodology emphasizes verified, data-backed insights rather than speculative claims. Qualitative assessment was applied to identify growth drivers, unmet needs, adoption barriers, technology impact, and regional differences across substance abuse treatment services, medication-assisted treatment, telehealth, harm reduction, relapse prevention, and recovery support ecosystems.

Conclusion: A Market Defined by Access and Outcomes

The substance abuse treatment market is entering a decisive period as governments, payers, providers, and communities recognize addiction as a chronic, treatable health condition. Demand is supported by high unmet need, overdose prevention priorities, wider use of medication-assisted treatment, and integration with mental healthcare.

Organizations that combine clinical quality, scalable access, digital enablement, and patient-centered recovery support will be best positioned to improve outcomes and support sustainable growth. The strongest strategies will align evidence-based care with regional policy realities, reimbursement incentives, privacy requirements, workforce readiness, and measurable public health impact.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Substance Abuse Treatment Market, by Treatment Mode

• 7.1. Day Treatment
• 7.2. Detoxification
  • 7.2.1. Medical Detox
  • 7.2.2. Non Medical Detox
• 7.3. Inpatient
  • 7.3.1. Hospital Based Inpatient
  • 7.3.2. Residential Inpatient
• 7.4. Outpatient
  • 7.4.1. Intensive Outpatient Program
  • 7.4.2. Standard Outpatient Program
• 7.5. Telehealth
  • 7.5.1. Asynchronous Telehealth
  • 7.5.2. Synchronous Telehealth

8. Substance Abuse Treatment Market, by Substance Type

• 8.1. Alcohol
• 8.2. Cannabis
• 8.3. Opioids
• 8.4. Stimulants

9. Substance Abuse Treatment Market, by Drug Class

• 9.1. Opioid Antagonists
• 9.2. Detoxification Medications
• 9.3. Anti Craving Medications

10. Substance Abuse Treatment Market, by End User

• 10.1. Clinic
• 10.2. Homecare
• 10.3. Hospitals
• 10.4. Rehabilitation Centers

11. Substance Abuse Treatment Market, by Distribution Channel

• 11.1. Online
• 11.2. Offline

12. Substance Abuse Treatment Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Substance Abuse Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Substance Abuse Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AbbVie Inc.
• 16.2. Acadia Healthcare Company Inc.
• 16.3. Alkermes plc
• 16.4. Amneal Pharmaceuticals Inc.
• 16.5. AstraZeneca PLC
• 16.6. Bausch Health Companies Inc.
• 16.7. BioCorRx Inc.
• 16.8. Braeburn Inc.
• 16.9. Camurus AB
• 16.10. Cipla Limited
• 16.11. Dr. Reddy's Laboratories Ltd.
• 16.12. Eli Lilly and Company
• 16.13. Emergent BioSolutions Inc.
• 16.14. Glenmark Pharmaceuticals Ltd.
• 16.15. GSK plc
• 16.16. Hikma Pharmaceuticals plc
• 16.17. Indivior PLC
• 16.18. Lannett Company Inc.
• 16.19. Lupin Limited
• 16.20. Mallinckrodt Pharmaceuticals plc
• 16.21. Novartis AG
• 16.22. Orexo AB
• 16.23. Perrigo Company plc
• 16.24. Pfizer Inc.
• 16.25. Sanofi S.A.
• 16.26. Sun Pharmaceutical Industries Ltd.
• 16.27. Teva Pharmaceutical Industries Ltd.
• 16.28. Viatris Inc.
• 16.29. Zydus Lifesciences Limited